Margaret Porter Scott

List of Publications by Year
in descending order

23	5,167	377584	721071
papers	citations	21	23
		h-index	g-index

23	23	23	7369
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell, 2019, 36, 100-114.e25.	7.7	196
2	Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLoS ONE, 2018, 13, e0197372.	1.1	45
3	Identification of a peptide inhibitor for the histone methyltransferase WHSC1. PLoS ONE, 2018, 13, e0197082.	1.1	22
4	Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Scientific Reports, 2017, 7, 17993.	1.6	85
5	Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Medicinal Chemistry Letters, 2016, 7, 162-166.	1.3	113
6	Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP. Biochemistry, 2016, 55, 1645-1651.	1.2	16
7	Structural Insights into Ternary Complex Formation of Human CARM1 with Various Substrates. ACS Chemical Biology, 2016, 11, 763-771.	1.6	34
8	A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening. Journal of Biomolecular Screening, 2015, 20, 810-820.	2.6	38
9	A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nature Chemical Biology, 2015, 11, 432-437.	3.9	442
10	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Medicinal Chemistry Letters, 2015, 6, 491-495.	1.3	107
11	Reaction Coupling between Wild-Type and Disease-Associated Mutant EZH2. ACS Chemical Biology, 2014, 9, 2459-2464.	1.6	29
12	DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents inMLL-Rearranged Leukemia Cells. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 646-656.	1.3	98
13	Nonclinical pharmacokinetics and metabolism of EPZâ€5676, a novel DOT1L histone methyltransferase inhibitor. Biopharmaceutics and Drug Disposition, 2014, 35, 237-252.	1.1	66
14	Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood, 2013, 122, 1017-1025.	0.6	608
15	Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7922-7927.	3.3	639
16	Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys27 methylation by human polycomb repressive complex 2 and vSET. Biochemical Journal, 2013, 453, 241-247.	1.7	7
17	A687V EZH2 is a gainâ€ofâ€function mutation found in lymphoma patients. FEBS Letters, 2012, 586, 3448-3451.	1.3	128
18	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature Chemical Biology, 2012, 8, 890-896.	3.9	698

#	Article	IF	Citations
19	Chemogenetic Analysis of Human Protein Methyltransferases. Chemical Biology and Drug Design, 2011, 78, 199-210.	1.5	167
20	The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Letters, 2011, 585, 3011-3014.	1.3	80
21	Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor. Cancer Cell, 2011, 20, 53-65.	7.7	842
22	Targeting epigenetic enzymes for drug discovery. Current Opinion in Chemical Biology, 2010, 14, 505-510.	2.8	99
23	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20980-20985.	3.3	608